Announced details
Preparedness for threats to national health security, including Gram-negative bacterial infections and antimicrobial resistance (AMR). The contract also covers the expansion of indications to include infections caused by priority pathogens and hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) in pediatric patients.
A contract concerning cefiderocol was signed on 8 April 2026. Under the contract, the U.S. government exercised its procurement option.
A U.S. government agency. BARDA oversees Project BioShield, which accelerates the research and development, procurement, and supply of medical countermeasures against CBRN threats. Location, representative, capital, and year established: Not disclosed.
Contract number 75A50126C00004. Expiry date: Not disclosed.
The contract option includes establishing a pharmaceutical manufacturing facility for cefiderocol in the United States, but the location is Not disclosed.
The company will receive US$36.9 million. It received US$119 million in funding during the initial phase following execution of the contract and may receive up to US$482 million in funding as the related options progress.
The impact on consolidated results for the fiscal year ending March 2027 is immaterial.
The company does not address Offering price.
U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA)
Project BioShield
Contract number 75A50126C00004
| Item | Details |
|---|---|
| Names of Products / Services Covered | Cefiderocol, Fetroja® |
| Counterparty | The U.S. government through the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) |
| Counterparty overview | A U.S. government agency. BARDA oversees Project BioShield, which accelerates the research and development, procurement, and supply of medical countermeasures against CBRN threats. Location, representative, capital, and year established: Not disclosed. |
| Relationship with the Company | A contract concerning cefiderocol was signed on 8 April 2026. Under the contract, the U.S. government exercised its procurement option. |
| Contract Value | The company will receive US$36.9 million. It received US$119 million in funding during the initial phase following execution of the contract and may receive up to US$482 million in funding as the related options progress. |
| Contract Date | 8 April 2026 |
| Applicable area | Preparedness for threats to national health security, including Gram-negative bacterial infections and antimicrobial resistance (AMR). The contract also covers the expansion of indications to include infections caused by priority pathogens and hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) in pediatric patients. |
| Registration number and expiry date | Contract number 75A50126C00004. Expiry date: Not disclosed. |
| Location | The contract option includes establishing a pharmaceutical manufacturing facility for cefiderocol in the United States, but the location is Not disclosed. |
| Impact on Business Performance | The impact on consolidated results for the fiscal year ending March 2027 is immaterial. |
| Source | U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA), Project BioShield, Contract number 75A50126C00004 |
Items this document does not state (7)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The U.S. government exercised the procurement option through Project BioShield to strengthen preparedness for threats to national health security, including antimicrobial resistance (AMR).